1stOncology™: Cancer Intelligence Service – Page 13 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

BostonGene to Feature Next-Generation AI Foundation Models for Precision Immuno-Oncology at the 22nd Annual RadMed Symposium

On June 10, 2026 BostonGene, leading developer of AI models for tumor and immune biology, reported its participation at the 22nd Annual Industry/Academia Precision Oncology & RadMed Symposium. At this premier event, global leaders in life sciences will explore the latest innovations in AI, immuno-oncology, molecular imaging, and targeted therapies. The symposium will be held on Thursday, June 11, 2026, at The Alexandria at Torrey Pines Conference Center in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Presentation details:

Title: Beyond Multiomics: Leveraging AI Foundation Models to Decode the Tumor-Immune Interface
Date & time: Thursday, June 11 | 1:25 PM PST
Speaker: Michael F. Goldberg, PhD, VP of R&D, BostonGene
The presentation will showcase how BostonGene utilizes advanced AI architecture and foundation models to integrate multimodal oncology and immunology data spanning molecular, tissue, cellular, and patient levels to deliver deep biological insights and accelerate drug development. Trained on extensive data points across multiple indications, this model generates high-dimensional embeddings that significantly improve the prediction of immunotherapy response and toxicity profiles.

Dr. Goldberg will highlight how AI-based analysis of minimally invasive peripheral blood immune profiling can support clinical development. The presentation will include key findings from a large-scale clinical collaborative study, demonstrating how the platform predicts patient response and toxicity, mitigates overfitting, and unlocks rare biological signals to guide patient stratification.

To learn more or to schedule a meeting with BostonGene during the event, please contact Hannah Oman at [email protected]. For additional details, visit the 22nd Annual Industry/Academia Precision Oncology & RadMed Symposium website.

(Press release, BostonGene, JUN 10, 2026, View Source [SID1234666554])

Laverock Therapeutics Reports Key Oncology Research Milestones

On June 10, 2026 Laverock Therapeutics (‘Laverock’), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, reported key in-vivo functional milestones across its T-cell and macrophage oncology programmes for solid tumour indications. The data support lead programme selection and progression towards the clinic.

Laverock’s platform technology enables programmable, tunable and multiplex gene control for both endogenous targets and for transgenically expressed payloads. In its T-cell programme (LVK201), the platform is designed to improve CAR-T cell anti-tumour activity without compromising safety. The latest data from ovarian cancer models, presented at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting in May, demonstrate that the Company’s technology can improve solid tumour control by targeting three distinct immunomodulatory pathways simultaneously. Previous studies have also shown that, because the technology harnesses T-cell activation dynamics to act only when needed, safety can be significantly improved compared with alternative approaches.

These findings inform development of Laverock’s lead programme whilst also providing broader validation of the platform, establishing a foundation for future tailored therapies across a range of solid tumour types. To realise this Laverock will apply AI and single-cell analytical approaches backed by recently announced grant funding.

In its macrophage programme (LVK301), Laverock’s platform technology is used to control macrophage cell phenotype and regulate the delivery of an immunomodulatory payload. The Company has shown that these engineered cells can both control tumour growth, and convert the ‘cold’, immunosuppressive solid tumour microenvironment to a ‘hot’ state, enabling the body’s immune system to attack the tumour. These findings provide strong validation of Laverock’s macrophage programme for oncology and open the way to applying myeloid biology to address additional disease classes.

Laverock is now engaged with a range of partner organisations, defining non-clinical and clinical strategy, to provide a de-risked route to early clinical validation.

David Venables, Laverock Therapeutics CEO, said: "These key data points from our oncology programmes highlight the capabilities and strength of our platform technology, and provide a clear route to lead programme selection and progression into non-clinical studies. Solid tumours remain an area of huge unmet need for cancer patients, and we look forward to moving our differentiated therapies towards the clinic."

(Press release, Laverock Therapeutics, JUN 10, 2026, View Source [SID1234666553])

MTTI Highlights Clinical Experience in 81 GEP-NETs Patients and Differentiated Profile of Next-Generation PRRT Candidate EBTATE Following Presentation at SNMMI 2026

On June 10, 2026 Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage radiopharmaceutical company developing next-generation albumin-binding targeted radiotherapeutics, reported updated clinical findings from patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with its lead investigational product candidate, ¹⁷⁷Lu-DOTA-EB-TATE (EBTATE), following presentation at the 2026 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.

The 81-patient experience represents one of the largest clinical datasets reported to date for an albumin-binding peptide receptor radionuclide therapy (PRRT) and provides growing evidence that EBTATE may offer a differentiated and potentially best-in-class profile compared with conventional PRRT approaches.

Key Clinical Highlights from 81 Treated GEP-NET Patients

Approximately 8-fold higher tumor uptake compared with conventional PRRT
50% objective response rate (ORR)
100% disease control rate (DCR)
36-month median progression-free survival (PFS)
No observed kidney toxicity through one year of follow-up
Equivalent renal absorbed dose with or without amino acid infusion
Potential two-cycle treatment regimen versus the conventional four-cycle PRRT
Clinical activity achieved using only approximately 12.5% of the cumulative radioactivity administered in current standard-of-care PRRT
The findings further validate MTTI’s proprietary Evans Blue (EB) technology platform, which utilizes reversible albumin binding to extend circulation time, enhance tumor uptake, and increase tumor retention. Preclinical studies have demonstrated up to 26-fold higher tumor retention compared with conventional radiopharmaceutical approaches, supporting broad applicability across multiple radionuclides, targeting vectors, and tumor types.

"The clinical experience in 81 patients validates both EBTATE and the broader Evans Blue platform," said Chris Pak, Chairman and Chief Executive Officer of MTTI. "By improving tumor delivery and retention while requiring only approximately 12.5% of the cumulative radioactivity administered in current standard-of-care PRRT, the platform has the potential to enhance the therapeutic index of radiopharmaceuticals across multiple cancers and with both beta- and alpha-emitting radionuclides. The combination of enhanced tumor uptake, prolonged tumor retention, favorable clinical responses, and robust safety observations supports the continued development of EBTATE and highlights the broader potential of the Evans Blue platform to improve targeted radiotherapeutics across a wide range of solid tumors."

"EBTATE achieved markedly higher tumor uptake and longer tumor retention than conventional ¹⁷⁷Lu-DOTATATE while maintaining a favorable safety profile," said Lisa Bodei, MD, PhD, a nuclear medicine physician at Memorial Sloan Kettering Cancer Center and recipient of the 2026 Castle Connolly America’s Top Doctor Award. "The ability to deliver higher radiation doses to tumors with significantly lower administered radioactivity highlights the potential of this albumin-binding approach to improve the therapeutic index of PRRT. This data from NET patients supports continued clinical development and further evaluation of a streamlined treatment regimen."

(Press release, Molecular Targeting Technologies, JUN 10, 2026, View Source [SID1234666552])

Cosylab and Heron Neutron Medical Corp. Sign Letter of Intent to Advance Global Deployment of Accelerator-Based BNCT Systems

On June 10, 2026 Cosylab and Heron Neutron Medical Corp. reported the signing of a Letter of Intent to establish a strategic framework for joint market development to support the global deployment of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems.

The collaboration aims to accelerate the development and integration of sophisticated software solutions for use with AB-BNCT while strengthening AB-BNCT’s international market access and business development. By combining Cosylab’s proven expertise in mission-critical software and complex system integration with Heron’s end-to-end BNCT platforms, the partnership aims to drive broader global clinical adoption of this highly targeted cancer treatment modality.

"AB-BNCT is emerging as one of the most promising approaches for treating difficult-to-treat and recurrent cancers," said Mark Pleško, Chief Executive Officer of Cosylab. "This collaboration reinforces our strategic focus on advancing radiation therapy technologies and expanding our reach in the Asia-Pacific region and beyond. We are committed to delivering impactful joint projects with Heron that accelerate market readiness and clinical adoption."

"This agreement represents a key step in Heron’s international growth strategy," underlined Shen Hsiao-Lien, General Manager of Heron Neutron Medical Corp. "Working with Cosylab will strengthen our cross-regional capabilities and support the rapid scaling of AB-BNCT solutions in markets worldwide."

(Press release, Heron Neutron Medical, JUN 10, 2026, View Source [SID1234666551])

PhoreMost Announces Lead Oncology Programme and Appoints Chief Medical Officer to Support Clinical Entry

On June 10, 2026 PhoreMost Limited ("PhoreMost"), a biotech company focused on turning scientific breakthroughs into life-changing cancer drugs, reported its lead programme, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers. The milestone marks the Company’s progress towards first-in-human clinical trials, with a pipeline of differentiated and first-in-class assets in oncology.

PMC-001 is a highly differentiated, orally bioavailable MTA, positioned to treat primary brain cancers, including glioblastoma, and secondary brain cancers frequently metastasising from advanced lung, breast and other tumour types, with strong potential for further indication expansion. While existing MTAs, such as taxanes, are broadly effective against multiple cancer types, they exhibit a lack of oral bioavailability and blood-brain barrier penetration. Primary and secondary brain cancers represent areas of significant unmet clinical need and high prevalence, creating a multibillion-dollar market opportunity.

PMC-001 is a small molecule with favourable drug-like properties possessing oral activity, CNS-penetration and ease of scaling. Preclinical safety and toxicology studies have demonstrated strong anti-tumour efficacy with excellent tolerability across diverse oncology-focussed models with an attractive dosing regimen. CMC has now been completed and PhoreMost is preparing imminent regulatory filings for trial initiation. The programme originates from the Company’s longstanding collaboration with Sentinel Oncology, with PhoreMost now taking the candidate forward.

Gabriel Fox, MB BChir, joins PhoreMost as Consulting Chief Medical Officer to lead the clinical development of PMC-001. Dr Fox completed his medical training at the University of Cambridge and brings 30 years of industry experience from global pharmaceutical companies such as Roche and Gilead Sciences, spanning the entire drug development process.

Dr Neil Torbett, CEO of PhoreMost, said: "PMC-001 shows striking tumour growth inhibition and holds great promise in delivering clinical benefit to patient groups that represent the highest areas of unmet need – announcing the programme is a fantastic milestone. With Gabriel’s extensive experience, we are excited to build on the impressive preclinical proof points and progress towards first-in-human trials, to deliver on our promise of unlocking the next generation of medicines."

Dr Gabriel Fox, Consulting CMO of PhoreMost, added: "I am thrilled to be joining PhoreMost as it reaches this significant milestone and approaches clinical stage. PMC-001 has performed exceptionally well in preclinical studies, the nature of the asset and mechanism of action is particularly impressive and will deliver clinical efficacy inflections rapidly. PMC-001 is well positioned to make a real difference. Having seen first-hand the patient need for new treatment options for both primary brain cancers and cancers with brain metastases, I am excited to be a part of the team moving it into the clinic."

(Press release, PhoreMost, JUN 10, 2026, View Source [SID1234666550])